These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1378883)

  • 21. [Chemotherapy and immunoprophylaxis of HIV infection].
    Vogt M; Schooley RT; Hirsch MS
    Schweiz Rundsch Med Prax; 1986 Nov; 75(48):1471-5. PubMed ID: 2432642
    [No Abstract]   [Full Text] [Related]  

  • 22. The growth advantage conferred by HIV-1 nef is determined at the level of viral DNA formation and is independent of CD4 downregulation.
    Chowers MY; Pandori MW; Spina CA; Richman DD; Guatelli JC
    Virology; 1995 Oct; 212(2):451-7. PubMed ID: 7571414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Agents for treating human immunodeficiency virus infection.
    Acosta EP; Fletcher CV
    Am J Hosp Pharm; 1994 Sep; 51(18):2251-67; quiz 2286-7. PubMed ID: 7801986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of HTLV-III/LAV replication by foscarnet.
    Sarin PS; Taguchi Y; Sun D; Thornton A; Gallo RC; Oberg B
    Biochem Pharmacol; 1985 Nov; 34(22):4075-9. PubMed ID: 2415134
    [No Abstract]   [Full Text] [Related]  

  • 25. A rodent cell line permissive for entry and reverse transcription of human immunodeficiency virus type 1 has a pre-integration block to productive infection.
    Simon JH; Schockmel GA; Illei P; James W
    J Gen Virol; 1994 Oct; 75 ( Pt 10)():2615-23. PubMed ID: 7523578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Site-specific mutagenesis of AIDS virus reverse transcriptase.
    Larder BA; Purifoy DJ; Powell KL; Darby G
    Nature; 1987 Jun 25-Jul 1; 327(6124):716-7. PubMed ID: 2439916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral effects of phosphonoformate (PFA, foscarnet sodium).
    Oberg B
    Pharmacol Ther; 1982; 19(3):387-415. PubMed ID: 6201932
    [No Abstract]   [Full Text] [Related]  

  • 28. The effect of trimeric 2',5'-oligoadenylic acid and its epoxy-derivative on human immunodeficiency virus (HIV-1) reproduction and retroviruses reverse transcriptase activity.
    Tkachuk ZYu ; Rybalko SL; Semernikova LI; Tkachuk VV; Zavelevich MP; Tkachuk LV; Eremenko T; Mikhailopulo IA; Matsuka GK
    New Microbiol; 1998 Apr; 21(2):197-201. PubMed ID: 9579344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587.
    Tramontano E; Cheng YC
    Biochem Pharmacol; 1992 Mar; 43(6):1371-6. PubMed ID: 1373283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors.
    O'Brien WA; Namazi A; Kalhor H; Mao SH; Zack JA; Chen IS
    J Virol; 1994 Feb; 68(2):1258-63. PubMed ID: 7507180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inactivation of human immunodeficiency virus type 1 reverse transcriptase by oltipraz: evidence for the formation of a stable adduct.
    Chavan SJ; Bornmann WG; Flexner C; Prochaska HJ
    Arch Biochem Biophys; 1995 Dec; 324(1):143-52. PubMed ID: 7503549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1.
    Koshida R; Cox S; Harmenberg J; Gilljam G; Wahren B
    Antimicrob Agents Chemother; 1989 Dec; 33(12):2083-8. PubMed ID: 2533474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.
    Bouchonnet F; Dam E; Mammano F; de Soultrait V; Henneré G; Benech H; Clavel F; Hance AJ
    J Virol; 2005 Jan; 79(2):812-22. PubMed ID: 15613309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative assessment of antiretrovirals in human monocyte-macrophages and lymphoid cell lines acutely and chronically infected with the human immunodeficiency virus.
    Crowe SM; McGrath MS; Elbeik T; Kirihara J; Mills J
    J Med Virol; 1989 Nov; 29(3):176-80. PubMed ID: 2533247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate.
    Sandstrom EG; Kaplan JC; Byington RE; Hirsch MS
    Lancet; 1985 Jun; 1(8444):1480-2. PubMed ID: 2409414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. All-trans retinoic acid attacks reverse transcriptase resulting in inhibition of HIV-1 replication.
    Maeda Y; Yamaguchi T; Hijikata Y; Morita Y; Tanaka M; Hirase C; Takai S; Tatsumi Y; Kanamaru A
    Hematology; 2007 Jun; 12(3):263-6. PubMed ID: 17558705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-10 inhibits initial reverse transcription of human immunodeficiency virus type 1 and mediates a virostatic latent state in primary blood-derived human macrophages in vitro.
    Montaner LJ; Griffin P; Gordon S
    J Gen Virol; 1994 Dec; 75 ( Pt 12)():3393-400. PubMed ID: 7527834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Stability of human immunodeficiency virus to azidothymidine. II. Kinetic characteristics of "AZT-resistant" mutant forms of reverse transcriptase].
    Pokholok DK; Gudima SO; Memelova LV; Esipov DS; Rechinskiĭ VO; Kochetkov SN
    Biokhimiia; 1996 Jan; 61(1):142-51. PubMed ID: 8679772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
    Naeger LK; Margot NA; Miller MD
    Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
    Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
    Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.